Abstract 0878: In PsA pts w/ lateral epicondyle enthesitis on secukinumab (n=11): 🔹 Improved DAPSA & SPARCC scores 🔹 entheseal tissue biopsy showing shift toward pro-resolving fibroblasts (↑DKK3/CD200⁺) 🔹 ↓ osteoblast-related pathways @RheumNow #ACR25

X-sectional study by Dr Toledano et al showed that 20% (46/230) PsA pts had restless leg syndrome (RDS). Pts w/ RDS: - Polyarthritis ⬆️ Swollen jts ⬆️ Fatigue, anxiety, depression ⬆️ Dse activity Poor sleep quality Polyarthritis & Pso: assocd w/ RDS #ACR25 @RheumNow Abs1413 https://t.co/8Ds3TgLjs1

• https://x.com/RHEUMarampa/status/1982839712034230299/photo/1

In ICONIC-LEAD, adolescents (12 to <18 years) with moderate-to-severe psoriasis treated with icotrokinra (ICO) achieved Investigator Global Assessment (IGA) 0/1 in 84.1% vs 27.3% (placebo) and PASI 90 in 70.5% vs 13.6% at Week 16. Week 24 responses reached 88.6%. Safety profile https://t.co/L7h8BlnWaO

• https://x.com/synovialjoints/status/1982839707932483871/photo/1

A post-hoc analysis from the ReFlaP study showed that there was a significant correlation between PsAID12 & HAQ scores MDA-PsAIDrem (SN 82.6% SP97.1%) and MDA-PsAIDlow (SN 90.7% SP 91.2%) Potential alternative for HAQ in MDA criteria? #ACR25 @RheumNow Abs1411 https://t.co/QAxKsuhtDq

• https://x.com/RHEUMarampa/status/1982832157505589530/photo/1
• https://x.com/RHEUMarampa/status/1982832157505589530/photo/1

In high-risk psoriasis patients with nail disease, Secukinumab reduced PsA onset over 5 years with a total exposure of 1022 patient-years. Annual incidence dropped from 2.7 to 0.49 per 100 patient-years. Data from the real world SERENA study. Abstract 1463 @RheumNow #ACR25

POETYK-PsA 1 & 2 Phase 3 RCT TYK2i Deucravacitinib Pooled analysis 640+pts PBO vs. 640+pts DEUCRA 6mg QD MDA 12% vs 22% All elements of MDA response sig different except for Leeds enthesitis index DAPSA Remission 2% vs. 9% PsARC 42% vs. 61% PASDAS -1 vs. -1.7 mCPDAI -1.2 vs. -1.9 https://t.co/OTOFxTOrRp

• https://x.com/AurelieRheumo/status/1982831486026826168/photo/1
• https://x.com/AurelieRheumo/status/1982831486026826168/photo/1

GLP-1 receptor agonists reduce mortality in PsA Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA not After propensity matching, those treated with GLP-1: - lower risk MACE - lower risk overall death @RheumNow #ACR25 Abst 0849 https://t.co/EuojrDq0Fj

• https://x.com/Dr_Brian_MD/status/1982830407365341680/photo/1

In pooled PsA trials (n=1222), deucravacitinib reduced disease activity–linked proteomic scores in both sexes by Week 16. Proteomic profiling identified 133 unique proteins in males and 177 in females vs sex-matched healthy controls. Females showed greater enrichment in https://t.co/TTAWUtOLP0

• https://x.com/synovialjoints/status/1982829640927551627/photo/1

Abstract 0874: At wk16, deucravacitinib (vs placebo) showed greater efficacy in multiple #PsA disease activity measures 🔹 ↑ MDA, DAPSA LDA/remission, and PsARC responses 🔹 Greater ↓in PASDAS and mCPDAI 🔹 Benefits seen in both men and women @RheumNow #ACR25

Sex based differences in PsA proteomics Analyse from POETYK PSA 1 & 2 deucravacitinib RCT Large overlap but female pts specificities, Upregulation of: -JAK STAT pathway -Cytokine interaction Linked with higher disease activity in female groups Yes Correlation, but not https://t.co/VwiVOkxpoB

• https://x.com/AurelieRheumo/status/1982827696372535302/photo/1
• https://x.com/AurelieRheumo/status/1982827696372535302/photo/1

This retrospective study evaluated incidence of MACE & mortality among PsA pts on GLP-1RAs vs non-GLP-1RAs After propensity score matching, pts on GLP-1RAs = ⬇️ risk of developing MACE & ⬇️ mortality vs. non GLP-1RAs Interesting data, More research reqd #ACR25 @RheumNow Abs0849 https://t.co/hiPpQH0K3O

• https://x.com/RHEUMarampa/status/1982802974314254418/photo/1
• https://x.com/RHEUMarampa/status/1982802974314254418/photo/1

TriNetX database 4000+ pts PsA + GLP-1 RA & 86000+ PsA non GLP-1 ctrls Without much surprise GLP-1 treated pts had lower risk of MACE and death Observational, retrospective study. Now awaiting the prospective evidence. RCT on the way but capturing MACE and death are always https://t.co/GWbAMC1mJK

• https://x.com/AurelieRheumo/status/1982803333078225298/photo/1

What is better in #PsA post #TNFi? #RCT of #secukinumab v #ustekinumab The big 🤔? #IL17Ai vs IL12/23i 🏆 #Cosentyx ✈️✅PASI ⚜️✅ACR50 Will H2H studies change our #prescribing?🤷‍♀️ #rheums Rx #IL17i>#IL12i/23i vs #derms #ACRBest #ACR25 @RheumNow @ACRheum abst#LB06 https://t.co/RpC8ymDc7H

• https://x.com/Janetbirdope/status/1982822570379325563/photo/1

To #cycle within or go to another drug class I #axSpA? #RCT of #TNFi-IR 👇 2nd #TNFi v #IL17i #IJDM it doesn’t matter what choice as #IL17i WAS NOT superior to TNFi cycling from 1st -2nd 👍 stay in #TNFi class = change to #IL17i #ACR25 @RheumNow abst#LB09 #ACRBest @ACRheum https://t.co/VCdL5CUYUa

• https://x.com/Janetbirdope/status/1982822671504085337/photo/1
• https://x.com/Janetbirdope/status/1982822671504085337/photo/1